- US-listed companies
- ACURA PHARMACEUTICALS, INC
ACURA PHARMACEUTICALS, INCACUR
Market cap
P/E ratio
| Dec 31, 2011 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | |
| Royalties | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Other Sale Revenues Net | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Revenue From License Fee | - | - | - | - | - | - | - | 2 | 3 | 1 |
| Product sales | - | - | - | - | - | - | - | - | 0 | - |
| Total revenues | 20 | 0 | 1 | 9 | 4 | 3 | 0 | 3 | 4 | 2 |
| Research and development | 4 | 5 | 5 | 3 | 4 | 4 | 2 | 2 | 2 | 2 |
| General and administrative | 6 | 9 | 8 | 9 | 7 | 4 | 3 | 2 | 3 | 1 |
| Total expenses | 10 | 14 | 13 | 13 | 11 | 8 | 4 | 3 | 4 | 3 |
| Operating loss | 11 | -14 | -12 | -4 | -7 | -5 | -4 | -1 | -1 | -1 |
| Gain on forgiveness of a loan under CARES Act | - | - | - | - | - | - | - | - | - | 1 |
| Interest expense to related party | - | - | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Loss before provision for income taxes | 11 | -14 | -13 | -5 | -7 | -6 | -4 | -4 | -1 | -1 |
| Provision for income taxes | 0 | - | - | - | - | -0 | - | - | - | - |
| Net loss | 10 | -14 | -13 | -5 | -7 | -6 | -4 | -4 | -1 | -1 |
| Basic | 0.22 | -0.29 | -0.27 | -0.46 | -0.62 | -0.36 | -0.18 | -0.14 | -0.04 | -0.02 |
| Diluted | 0.22 | -0.29 | -0.27 | -0.46 | -0.62 | -0.36 | -0.18 | -0.14 | -0.04 | -0.02 |